ChemComm
Communication
Table 2 Enantioselective reaction of various indol-2-yl carbinols 8 with
indole 9aa
in excellent yields (490%) as well as high ee values (86–95%).
These results unambiguously exemplified that the asymmetric
reaction presented herein also displays a broad substrate scope
for indole nucleophiles. Finally, by replacing the catalyst
(R)-11a with (S)-11a, the corresponding enantiomers could also
be synthesized uneventfully in identically high yields and
enantioselectivities as seen from the data of 10u–10w vs.
ent-10u-ent-10w. These results would facilitate a clear investiga-
tion into the effect of chirality on anticancer properties.
In summary, we have developed a novel methodology that
has realized the asymmetric reaction of the inherently challen-
ging indol-2-yl carbinols. The protocol exhibits a broad compat-
ibility for these substrates and can proceed in a very simple,
clean, and atom-economical manner in the presence of the
most readily available BINOL-based phosphoramides as cata-
lysts. The unprecedented chiral 2,30-diindolylarylmethane
compounds synthesized in this work are interesting candidates
for the discovery of new anticancer drugs. In addition, the
established interaction model should be useful for the de novo
design of other types of asymmetric reactions related with
indol-2-yl carbinols. Currently, we are screening the anticancer
activity of the synthesized chiral diindolylarylmethanes and
exploring new conditions for the enantioselective reaction of
indol-2-yl carbinols with other appropriate p-nucleophiles. In
addition, the determination of the absolute configuration of
the products and the clarification of the reasons for why the
unsubstituted catalyst 11a afforded a better and reversed enan-
tioselectivity as compared to the 3,30-disubstituted catalysts are
also the focus of our current studies.
a
Reaction conditions: indol-2-yl carbinols 8 (0.1 mmol), indole 9a
(0.1 mmol), catalyst (R)-11a (10 mol%) in toluene (4 mL) at ꢀ60 1C
for 3–10 h, yield of isolated products; ee % was the average value of two
runs and was determined by HPLC on AD-H, OD-H, or OJ-H column (see
ESI for details); the reaction time was not optimized.
cyclopentyl (10k) were also compatible, although a bulkier R2
group led to a somewhat decreased enantioselectivity. Finally, an
array of R3 groups such as iPr (10a–10j), Me (10k), Bn (10l), and
PMB (10m) was also viable. These results exemplified that the
reaction exhibits a broad substrate scope for indol-2-yl carbinol
electrophiles.
To further demonstrate the broad generality and reliability
of the protocol, we examined the asymmetric reaction by
varying the indole nucleophiles 9. The results are summarized
in Table 3. Typically, indole nucleophiles with a variety of
substituents such as 5-F, Cl, Br, Me, and 4-F reacted smoothly
with 8a to deliver the corresponding diindolylarylmethanes
10n–10r both in good yield and enantioselectivity. Further-
more, a flexible combination of various indol-2-yl carbinols 8
and indole nucleophiles 9 showed that all the combinations
could also proceed very cleanly and efficiently under the
optimized conditions to afford the desired products 10s–10bb
Financial support from NSFC (21272225), and Key Lab of
Synthetic Chemistry of Natural Substances, SIOC, is acknowledged.
Notes and references
1 For reviews, see: (a) M. S. Shchepinov and V. A. Korshun, Chem. Soc.
Rev., 2003, 32, 170; (b) M. Shiri, M. A. Zolfigol, H. G. Kruger and
Z. Tanbakouchian, Chem. Rev., 2010, 110, 2250.
2 For a recent review, see: S. Safe, S. Papineni and S. Chintharlapalli,
Cancer Lett., 2008, 269, 326.
3 For selected examples, see: (a) C. Qin, D. Morrow, J. Stewart,
K. Spencer, W. Porter, R. Smith III, T. Phillips, M. Abdelrahim,
I. Samudio and S. Safe, Mol. Cancer Ther., 2004, 3, 247;
(b) S. Chintharlapalli, S. Papineni and S. Safe, Mol. Pharmacol.,
2007, 71, 558; (c) J. Guo, S. Chintharlapalli, S. O. Lee, S. D. Cho,
P. Lei, S. Papineni and S. Safe, Cancer Chemother. Pharmacol., 2010,
66, 141; (d) M. Abdelrahim, K. Newman, K. Vanderlaag, I. Samudio
and S. Safe, Carcinogenesis, 2006, 27, 717; (e) R. Contractor,
I. Samudio, Z. Estrov, D. Harris, J. A. McCubrey, S. Safe,
M. Andreeff and M. Konopleva, Cancer Res., 2005, 65, 2890;
( f ) W. Kassouf, S. Chintharlapalli, M. Abdelrahim, G. Nelkin,
S. Safe and A. M. Kamat, Cancer Res., 2006, 66, 412; (g) J. Hong,
I. Samudio, S. Chintharlapalli and S. Safe, Mol. Carcinog., 2008,
47, 492.
Table 3 Enantioselective reaction of a free combination of various indol-
2-yl carbinols 8 with indoles 9a
4 For an example, see: P. M. Wood, L. L. Woo, J.-R. Labrosse,
M. N. Trusselle, S. Abbate, G. Longhi, E. Castiglioni, F. Lebon,
A. Purohit and M. J. Reed, J. Med. Chem., 2008, 51, 4226.
5 (a) F.-L. Sun, X.-J. Zheng, Q. Gu, Q.-L. He and S.-L. You, Eur. J. Org.
Chem., 2010, 47; (b) M.-H. Zhuo, Y.-J. Jiang, Y.-S. Fan, Y. Gao, S. Liu
and S. Zhang, Org. Lett., 2014, 16, 1096.
6 (a) B. Xu, L.-L. Shi, Y.-Z. Zhang, Z.-J. Wu, L.-N. Fu, C.-Q. Luo,
L.-X. Zhang, Y.-G. Peng and Q.-X. Guo, Chem. Sci., 2014, 5, 1988;
(b) Q.-X. Guo, Y.-G. Peng, J.-W. Zhang, L. Song, Z. Feng and L.-Z.
Gong, Org. Lett., 2009, 11, 4620; (c) M. Rueping, B. J. Nachtsheim,
S. A. Moreth and M. Bolte, Angew. Chem., Int. Ed., 2008, 47, 593.
a
Reaction conditions: indol-2-yl carbinols 8 (0.1 mmol), indoles 9
(0.1 mmol), catalyst (R) or (S)-11a (10 mol%) in toluene (4 mL) at
ꢀ60 1C for 3–12 h. Isolated yield; ee % was the average value of two runs
and was determined by HPLC on an AD-H or OD-H column; the
reaction time was not optimized.
This journal is ©The Royal Society of Chemistry 2014
Chem. Commun., 2014, 50, 8605--8608 | 8607